Z Cui1, E Grafstein, B Yip, R Hogg, J S G Montaner, V D Lima. 1. British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada; Statistical Department, University of British Columbia, Vancouver, BC, Canada.
Abstract
OBJECTIVES: The extent to which clinical progression of HIV-positive patients leads to an increase in health care utilization, especially prior to their death, is unknown. Thus, we modelled trends in CD4 cell count and emergency department utilization and the likelihood of an emergency department visit leading to a transfer to an acute care-level facility prior to a patient's death from nonaccidental causes. METHODS: Eligible patients initiated highly active antiretroviral therapy (HAART) in British Columbia between August 1996 and June 2006 (n = 457). Patients were followed until their death, which occurred on or before 30 June 2007 (period in which the emergency department visit data were available). Trends were modelled using generalized mixed effects. RESULTS: Patients experienced a significantly steep decline in CD4 cell count and a corresponding increase in the number of emergency department visits and transfers to acute-level facilities in the 5 years prior to death. For every 6-month interval prior to death, the CD4 cell count decreased by 13.22 cells/μL, the risk of experiencing an emergency department visit increased by 9%, and among those ever admitted, the odds ratio of being transferred to an acute care-level facility increased by 3%. CONCLUSIONS: We showed that patients experienced a steep decline in CD4 cell count, which was associated with an increase in health care utilization prior to their death. These findings highlight the substantial residual avoidable burden that unsuccessfully managed HIV disease poses, even in the HAART era. Further strategies to enhance sustained and successful engagement in care are urgently needed to mitigate high health care utilization.
OBJECTIVES: The extent to which clinical progression of HIV-positivepatients leads to an increase in health care utilization, especially prior to their death, is unknown. Thus, we modelled trends in CD4 cell count and emergency department utilization and the likelihood of an emergency department visit leading to a transfer to an acute care-level facility prior to a patient's death from nonaccidental causes. METHODS: Eligible patients initiated highly active antiretroviral therapy (HAART) in British Columbia between August 1996 and June 2006 (n = 457). Patients were followed until their death, which occurred on or before 30 June 2007 (period in which the emergency department visit data were available). Trends were modelled using generalized mixed effects. RESULTS:Patients experienced a significantly steep decline in CD4 cell count and a corresponding increase in the number of emergency department visits and transfers to acute-level facilities in the 5 years prior to death. For every 6-month interval prior to death, the CD4 cell count decreased by 13.22 cells/μL, the risk of experiencing an emergency department visit increased by 9%, and among those ever admitted, the odds ratio of being transferred to an acute care-level facility increased by 3%. CONCLUSIONS: We showed that patients experienced a steep decline in CD4 cell count, which was associated with an increase in health care utilization prior to their death. These findings highlight the substantial residual avoidable burden that unsuccessfully managed HIV disease poses, even in the HAART era. Further strategies to enhance sustained and successful engagement in care are urgently needed to mitigate high health care utilization.
Keywords:
CD4 cell count; Canadian Triage and Acuity Scale (CTAS); emergency department visits; generalized mixed effect model; health care utilization; highly active antiretroviral therapy; mortality
Authors: John A Fleishman; Kelly A Gebo; Erin D Reilly; Richard Conviser; W Christopher Mathews; P Todd Korthuis; James Hellinger; Richard Rutstein; Philip Keiser; Haya Rubin; Richard D Moore Journal: Med Care Date: 2005-09 Impact factor: 2.983
Authors: Sheri D Weiser; Alexander C Tsai; Reshma Gupta; Edward A Frongillo; Annet Kawuma; Jude Senkungu; Peter W Hunt; Nneka I Emenyonu; Jennifer E Mattson; Jeffrey N Martin; David R Bangsberg Journal: AIDS Date: 2012-01-02 Impact factor: 4.177
Authors: Kathleen Falster; Handan Wand; Basil Donovan; Jonathan Anderson; David Nolan; Kerrie Watson; Jo Watson; Matthew G Law Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: Viviane Dias Lima; Thomas Kerr; Evan Wood; Tsubasa Kozai; Kate A Salters; Robert S Hogg; Julio S G Montaner Journal: AIDS Care Date: 2013-06-14
Authors: Ruth Joy; Eric F Druyts; Eirikka K Brandson; Viviane D Lima; Clare A Rustad; Wendy Zhang; Evan Wood; Julio S G Montaner; Robert S Hogg Journal: J Acquir Immune Defic Syndr Date: 2008-04-01 Impact factor: 3.731
Authors: Viviane D Lima; Josie Geller; David R Bangsberg; Thomas L Patterson; Mark Daniel; Thomas Kerr; Julio S G Montaner; Robert S Hogg Journal: AIDS Date: 2007-05-31 Impact factor: 4.177